Videos

Shawn Dason, MD, a urologic oncologist at The Ohio State University Comprehensive Cancer Center, discusses the decline of prostate cancer screening in recent years and how it has impacted care of patients with prostate cancer overall.

David Barrington, MD, discusses adjuvant treatments that are currently available for patients with stage 1B, grade 3 endometrial cancer.

Nazli Dizman, MD, discusses what community oncologists should keep in mind about gut microbiome when treating their patients.

John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.

Before closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.

Ajay K. Nooka, MD, MPH, FACP, shares insight on strategies to optimally deliver maintenance therapy and manage toxicities in patients with multiple myeloma.

Considerations for assessing treatment response and electing to continue therapy in patients with newly diagnosed multiple myeloma.

Insight on the role of isatuximab and VRd in patients with newly diagnosed multiple myeloma following data from the GMMG-HD7 study.

Shifting his focus to the MASTER study in newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, highlights the role of daratumumab with KRd.

Expert perspectives on the use of daratumumab with RVd in patients with newly diagnosed multiple myeloma in the context of updates from the GRIFFIN study.

Expert hematologist-oncologist Ajay K. Nooka, MD, MPH, FACP, shares his perspective on the management of a woman newly diagnosed with multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy with immunotherapy for patients with urothelial cancer.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.

Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

Hagop M. Kantarjian, MD, discusses the introduction of chimeric antigen receptor T cells and their impact on acute lymphoblastic leukemia.

Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.

Tanya Dorff, MD, discusses the recent findings from a phase 1 clinical trial which explored the use of chimeric antigen receptor T-cell therapy in patients with prostate cancer.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Oncologists discuss the use of carfilzomib for multiple myeloma and their typical treatment regimens of choice.

Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.

John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.

Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.

Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.

Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.

Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.